Badawi Mohamed Ali, Engelhardt Benjamin, Dobkowska Edyta, Deng Rong, Kaufman Jonathan L, Menon Rajeev, Salem Ahmed Hamed
Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.
Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
Invest New Drugs. 2024 Dec;42(6):635-643. doi: 10.1007/s10637-024-01471-x. Epub 2024 Oct 10.
Venetoclax is a first in class BCL-2 inhibitor, currently under investigation for the treatment of t(11;14) multiple myeloma (MM). The objective of this analysis was to characterize the exposure-efficacy and exposure-safety relationships of venetoclax when combined with carfilzomib and dexamethasone (VenKd) in t(11;14)-positive relapsed or refractory (R/R) MM patients from a phase 2 study. Fifty-seven patients receiving VenKd or Kd were included in the analysis. Efficacy endpoints included progression-free survival and clinical response rates of overall response, very good partial response or better and complete response or better. Grade ≥ 3 neutropenia, Grade ≥ 3 infections, Grade ≥ 3 treatment-emergent adverse events and any grade serious treatment-emergent adverse events were evaluated. The analysis demonstrated that adding venetoclax to Kd resulted in increased ORR, ≥VGPR and ≥ CR rates compared to the control arm. Within the venetoclax treatment arms (VenKd), no significant exposure-efficacy relationships were observed for ORR and ≥ VGPR rates. Higher ≥ CR rates trended with higher venetoclax exposures. While both 400 mg and 800 mg venetoclax in VenKd arms were generally tolerated, higher rates of Grade ≥ 3 neutropenia were observed with higher venetoclax exposures. Higher venetoclax exposures however were not associated with increased rates of Grade ≥ 3 treatment-emergent adverse events, Grade ≥ 3 infections, or serious treatment-emergent adverse events (any grade). These results confirm the benefit of adding venetoclax to carfilzomib and dexamethasone and support continued evaluation of venetoclax 400-800 mg once daily in this combination in t(11;14)-positive R/R MM patients. NCT02899052 registered April 18, 2017.
维奈克拉是首个同类BCL-2抑制剂,目前正在进行治疗t(11;14)多发性骨髓瘤(MM)的研究。本分析的目的是在一项2期研究中,对t(11;14)阳性复发或难治性(R/R)MM患者中,维奈克拉与卡非佐米和地塞米松联合使用(VenKd)时的暴露-疗效和暴露-安全性关系进行特征描述。分析纳入了57例接受VenKd或Kd治疗的患者。疗效终点包括无进展生存期以及总缓解、非常好的部分缓解或更好、完全缓解或更好的临床缓解率。评估了≥3级中性粒细胞减少、≥3级感染、≥3级治疗中出现的不良事件以及任何级别的严重治疗中出现的不良事件。分析表明,与对照组相比,在Kd方案中添加维奈克拉可提高客观缓解率(ORR)、≥非常好的部分缓解(≥VGPR)率和≥完全缓解(≥CR)率。在维奈克拉治疗组(VenKd)中,未观察到ORR和≥VGPR率与暴露之间存在显著的暴露-疗效关系。较高的≥CR率与较高的维奈克拉暴露量有关。虽然VenKd组中400mg和800mg维奈克拉通常都能耐受,但维奈克拉暴露量越高,≥3级中性粒细胞减少的发生率越高。然而,较高的维奈克拉暴露量与≥3级治疗中出现的不良事件、≥3级感染或严重治疗中出现的不良事件(任何级别)的发生率增加无关。这些结果证实了在卡非佐米和地塞米松方案中添加维奈克拉的益处,并支持在t(11;14)阳性R/R MM患者中继续评估维奈克拉每日一次400 - 800mg的这种联合用药方案。NCT02899052于2017年4月18日注册。